PEDIATRIX MEDICAL GROUP INC (MD) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:MD - US58502B1061 - Common Stock
24.08 USD
-0.01 (-0.04%)
24.01 USD
-0.07 (-0.29%)
We assign a fundamental rating of 5 out of 10 to MD. MD was compared to 101 industry peers in the Health Care Providers & Services industry. MD has an average financial health and profitability rating. MD scores decently on growth, while it is valued quite cheap. This could make an interesting combination. This makes MD very considerable for value investing!
1. Profitability
1.1 Basic Checks
In the past year MD was profitable.
In the past year MD had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: MD reported negative net income in multiple years.
MD had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
MD's Return On Assets of 7.37% is amongst the best of the industry. MD outperforms 90.10% of its industry peers.
Looking at the Return On Equity, with a value of 18.21%, MD belongs to the top of the industry, outperforming 86.14% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 10.25%, MD belongs to the top of the industry, outperforming 81.19% of the companies in the same industry.
MD had an Average Return On Invested Capital over the past 3 years of 7.83%. This is in line with the industry average of 9.22%.
The last Return On Invested Capital (10.25%) for MD is above the 3 year average (7.83%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.37% | ||
| ROE | 18.21% | ||
| ROIC | 10.25% |
ROA(3y)-1.5%
ROA(5y)-4.7%
ROE(3y)-4.21%
ROE(5y)-20.91%
ROIC(3y)7.83%
ROIC(5y)7.13%
1.3 Margins
MD has a better Profit Margin (8.44%) than 89.11% of its industry peers.
The Operating Margin of MD (12.20%) is better than 81.19% of its industry peers.
In the last couple of years the Operating Margin of MD has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.2% | ||
| PM (TTM) | 8.44% | ||
| GM | N/A |
OM growth 3Y-7.13%
OM growth 5Y-6.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so MD is still creating some value.
The number of shares outstanding for MD has been increased compared to 1 year ago.
MD has more shares outstanding than it did 5 years ago.
MD has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.28 indicates that MD is not a great score, but indicates only limited risk for bankruptcy at the moment.
MD has a Altman-Z score (2.28) which is in line with its industry peers.
The Debt to FCF ratio of MD is 2.20, which is a good value as it means it would take MD, 2.20 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 2.20, MD belongs to the best of the industry, outperforming 80.20% of the companies in the same industry.
A Debt/Equity ratio of 0.65 indicates that MD is somewhat dependend on debt financing.
MD has a Debt to Equity ratio of 0.65. This is comparable to the rest of the industry: MD outperforms 55.45% of its industry peers.
Although MD does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.65 | ||
| Debt/FCF | 2.2 | ||
| Altman-Z | 2.28 |
ROIC/WACC1.18
WACC8.69%
2.3 Liquidity
MD has a Current Ratio of 1.83. This is a normal value and indicates that MD is financially healthy and should not expect problems in meeting its short term obligations.
MD's Current ratio of 1.83 is fine compared to the rest of the industry. MD outperforms 71.29% of its industry peers.
A Quick Ratio of 1.83 indicates that MD should not have too much problems paying its short term obligations.
The Quick ratio of MD (1.83) is better than 74.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.83 | ||
| Quick Ratio | 1.83 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 56.92% over the past year.
The earnings per share for MD have been decreasing by -15.01% on average. This is quite bad
Looking at the last year, MD shows a decrease in Revenue. The Revenue has decreased by -4.21% in the last year.
Measured over the past years, MD shows a small growth in Revenue. The Revenue has been growing by 2.49% on average per year.
EPS 1Y (TTM)56.92%
EPS 3Y-2.95%
EPS 5Y-15.01%
EPS Q2Q%52.27%
Revenue 1Y (TTM)-4.21%
Revenue growth 3Y1.74%
Revenue growth 5Y2.49%
Sales Q2Q%-3.58%
3.2 Future
Based on estimates for the next years, MD will show a small growth in Earnings Per Share. The EPS will grow by 7.64% on average per year.
Based on estimates for the next years, MD will show a small growth in Revenue. The Revenue will grow by 2.71% on average per year.
EPS Next Y23.94%
EPS Next 2Y12.52%
EPS Next 3Y9.51%
EPS Next 5Y7.64%
Revenue Next Year-5.59%
Revenue Next 2Y-1.52%
Revenue Next 3Y0.03%
Revenue Next 5Y2.71%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 11.80, the valuation of MD can be described as very reasonable.
MD's Price/Earnings ratio is rather cheap when compared to the industry. MD is cheaper than 87.13% of the companies in the same industry.
When comparing the Price/Earnings ratio of MD to the average of the S&P500 Index (26.11), we can say MD is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 12.77, the valuation of MD can be described as correct.
MD's Price/Forward Earnings ratio is rather cheap when compared to the industry. MD is cheaper than 84.16% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of MD to the average of the S&P500 Index (36.21), we can say MD is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.8 | ||
| Fwd PE | 12.77 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MD indicates a rather cheap valuation: MD is cheaper than 80.20% of the companies listed in the same industry.
90.10% of the companies in the same industry are more expensive than MD, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.56 | ||
| EV/EBITDA | 8.09 |
4.3 Compensation for Growth
MD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MD has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)0.49
PEG (5Y)N/A
EPS Next 2Y12.52%
EPS Next 3Y9.51%
5. Dividend
5.1 Amount
MD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
24.08
-0.01 (-0.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners97.31%
Inst Owner Change-2.05%
Ins Owners1.9%
Ins Owner Change6.32%
Market Cap2.07B
Revenue(TTM)1.92B
Net Income(TTM)162.19M
Analysts78.67
Price Target23.12 (-3.99%)
Short Float %3.54%
Short Ratio3.53
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.41%
Min EPS beat(2)21.14%
Max EPS beat(2)39.68%
EPS beat(4)4
Avg EPS beat(4)32.13%
Min EPS beat(4)21.14%
Max EPS beat(4)39.68%
EPS beat(8)7
Avg EPS beat(8)18.68%
EPS beat(12)7
Avg EPS beat(12)8.95%
EPS beat(16)9
Avg EPS beat(16)6.72%
Revenue beat(2)1
Avg Revenue beat(2)-0.77%
Min Revenue beat(2)-1.97%
Max Revenue beat(2)0.42%
Revenue beat(4)2
Avg Revenue beat(4)-0.67%
Min Revenue beat(4)-1.97%
Max Revenue beat(4)0.42%
Revenue beat(8)2
Avg Revenue beat(8)-2.24%
Revenue beat(12)2
Avg Revenue beat(12)-2.22%
Revenue beat(16)3
Avg Revenue beat(16)-2.43%
PT rev (1m)36.68%
PT rev (3m)35.61%
EPS NQ rev (1m)16.45%
EPS NQ rev (3m)15.88%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.33%
Revenue NQ rev (1m)0.9%
Revenue NQ rev (3m)1.11%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.1%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.8 | ||
| Fwd PE | 12.77 | ||
| P/S | 1.08 | ||
| P/FCF | 7.56 | ||
| P/OCF | 7.13 | ||
| P/B | 2.32 | ||
| P/tB | N/A | ||
| EV/EBITDA | 8.09 |
EPS(TTM)2.04
EY8.47%
EPS(NY)1.89
Fwd EY7.83%
FCF(TTM)3.18
FCFY13.22%
OCF(TTM)3.38
OCFY14.02%
SpS22.39
BVpS10.37
TBVpS-4.42
PEG (NY)0.49
PEG (5Y)N/A
Graham Number21.82
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.37% | ||
| ROE | 18.21% | ||
| ROCE | 12.98% | ||
| ROIC | 10.25% | ||
| ROICexc | 13.79% | ||
| ROICexgc | 251.95% | ||
| OM | 12.2% | ||
| PM (TTM) | 8.44% | ||
| GM | N/A | ||
| FCFM | 14.22% |
ROA(3y)-1.5%
ROA(5y)-4.7%
ROE(3y)-4.21%
ROE(5y)-20.91%
ROIC(3y)7.83%
ROIC(5y)7.13%
ROICexc(3y)8.94%
ROICexc(5y)8.89%
ROICexgc(3y)78.23%
ROICexgc(5y)75.12%
ROCE(3y)9.91%
ROCE(5y)9.03%
ROICexgc growth 3Y26.95%
ROICexgc growth 5Y24.1%
ROICexc growth 3Y3.64%
ROICexc growth 5Y14.51%
OM growth 3Y-7.13%
OM growth 5Y-6.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.87
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.65 | ||
| Debt/FCF | 2.2 | ||
| Debt/EBITDA | 2.24 | ||
| Cap/Depr | 72.01% | ||
| Cap/Sales | 0.86% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 112.59% | ||
| Profit Quality | 168.57% | ||
| Current Ratio | 1.83 | ||
| Quick Ratio | 1.83 | ||
| Altman-Z | 2.28 |
F-Score8
WACC8.69%
ROIC/WACC1.18
Cap/Depr(3y)81.28%
Cap/Depr(5y)89.11%
Cap/Sales(3y)1.42%
Cap/Sales(5y)1.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.92%
EPS 3Y-2.95%
EPS 5Y-15.01%
EPS Q2Q%52.27%
EPS Next Y23.94%
EPS Next 2Y12.52%
EPS Next 3Y9.51%
EPS Next 5Y7.64%
Revenue 1Y (TTM)-4.21%
Revenue growth 3Y1.74%
Revenue growth 5Y2.49%
Sales Q2Q%-3.58%
Revenue Next Year-5.59%
Revenue Next 2Y-1.52%
Revenue Next 3Y0.03%
Revenue Next 5Y2.71%
EBIT growth 1Y42.45%
EBIT growth 3Y-5.51%
EBIT growth 5Y-4.62%
EBIT Next Year49.88%
EBIT Next 3Y15.85%
EBIT Next 5YN/A
FCF growth 1Y104.91%
FCF growth 3Y60.68%
FCF growth 5Y-11.42%
OCF growth 1Y73.9%
OCF growth 3Y39.11%
OCF growth 5Y-10.4%
PEDIATRIX MEDICAL GROUP INC / MD FAQ
What is the ChartMill fundamental rating of PEDIATRIX MEDICAL GROUP INC (MD) stock?
ChartMill assigns a fundamental rating of 5 / 10 to MD.
What is the valuation status of PEDIATRIX MEDICAL GROUP INC (MD) stock?
ChartMill assigns a valuation rating of 8 / 10 to PEDIATRIX MEDICAL GROUP INC (MD). This can be considered as Undervalued.
How profitable is PEDIATRIX MEDICAL GROUP INC (MD) stock?
PEDIATRIX MEDICAL GROUP INC (MD) has a profitability rating of 6 / 10.
How financially healthy is PEDIATRIX MEDICAL GROUP INC?
The financial health rating of PEDIATRIX MEDICAL GROUP INC (MD) is 5 / 10.
What is the expected EPS growth for PEDIATRIX MEDICAL GROUP INC (MD) stock?
The Earnings per Share (EPS) of PEDIATRIX MEDICAL GROUP INC (MD) is expected to grow by 23.94% in the next year.